Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

41 results about "Phosphorylethanolamine" patented technology

Phosphorylethanolamine or phosphoethanolamine is an ethanolamine derivative that is used to construct two different categories of phospholipids. One category termed a glycerophospholipid and the other a sphingomyelin, or more specifically within the sphingomyelin class, a sphingophospholipid. Phosphorylethanolamine is a polyprotic acid with two pKa values at 5.61 and 10.39.

Attenuated salmonella typhimurium EN-VNP strain as well as preparation method and application thereof

PendingCN119932072ABacteriaTransferasesEnzyme GenePhosphotransferase Gene
The invention discloses an attenuated salmonella typhimurium EN-VNP (Enhanced Natriuretic Peptide) strain as well as a preparation method and application of the attenuated salmonella typhimurium EN-VNP strain. Comprising the following steps: on the basis of a salmonella VNP20009 strain, flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU are sequentially knocked out or silenced, and a strain is formed after a phosphotransferase gene lpxE is knocked in or overexpressed, so that the attenuated salmonella typhimurium EN-VNP strain is prepared. According to the attenuated salmonella typhimurium EN-VNP with low toxicity and the T cell adjuvant effect and an EN-OMV antigen delivery system prepared from the attenuated salmonella typhimurium EN-VNP, an improved strain does not contain flagellin, an LPS molecular structure is changed, the attenuated salmonella typhimurium EN-VNP has the low toxicity and the T cell adjuvant effect, and normal multiplication culture can be achieved.
Owner:JIANGSU TARGET BIOMEDICINE RES INST

Bionic exosome for anti-inflammatory and repair as well as preparation method and application of bionic exosome

The invention relates to a bionic exosome for anti-inflammation and repair as well as a preparation method and application thereof, and belongs to the field of cosmetics. The bionic exosome provided by the invention comprises a membrane structure and an internal load phase, the membrane structure comprises a phospholipid bilayer, a stabilizer and a targeting ligand; the internal load phase comprises a solvent and an active component; the phospholipid bilayer is composed of phospholipid compounds; preferably, at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound, and at least one of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and the 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine is adopted as the phospholipid compound; at least one of cholesterol, phytosphingosine and sodium stearoyl glutamate is preferably adopted as a stabilizer, so that the stabilizer of the obtained bionic exosome is improved, and the bionic exosome has the advantages of high encapsulation efficiency, good encapsulation efficiency stability, simplicity in operation, excellent anti-inflammatory and repairing effects and the like.
Owner:GUANGZHOU FANZHIRONG COSMETICS CO LTD +1

Genetically engineered strain for reducing formation of by-products

PendingCN119101641ABacteriaGenetically modified cellsPhosphorylethanolamineGlucan biosynthesis
The present disclosure relates to the production of oligosaccharides, in particular human milk oligosaccharides (HMO), using genetically engineered cells of phosphoglycerotransferases I and II and / or phosphoethanolamine transferases and / or dextran biosynthetic protein C with reduced or completely lost function to reduce oligosaccharide byproducts and / or increase oligosaccharide yield.
Owner:DSM IP ASSETS BV

Cell membrane protein fusion liposome as well as preparation method and application thereof

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a cell membrane protein fusion lipidosome and a preparation method and application thereof.The cell membrane protein fusion lipidosome is prepared from dioleoyl lecithin, 1, 2-propylene glycol and 1, 3-propylene glycol according to the mass ratio of (3.17-7.17): (0.96-2.87): (0.86-2.57): (0.5-2.5): (0.5-2.5). The preparation method comprises the following steps of: adding 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[carboxyl (polyethylene glycol)-2000], cholesterol, triton X-100 and cell membrane protein; according to the cell membrane protein fusion liposome provided by the invention, the membrane protein loading rate is remarkably improved, and a technical support is provided for clinical application of a cell membrane material.
Owner:ZHIHUI MEDICAL TECH (SHANGHAI) CO LTD

Diagnostic marker for metabolic syndrome and preclinical stage thereof and application of diagnostic marker

PendingCN119246661AConducive to clinical promotion and applicationHelps with health managementMass spectrometric analysisMaterial analysis by electric/magnetic meansPipequalinePipecolic acid
The invention provides a diagnostic marker for metabolic syndrome and preclinical stage thereof, and the diagnostic marker or a plasma small molecule metabolism biomarker consists of the following substances: pyrimidine, (S)-beta-aminoisobutyric acid, 3-hydroxybutyric acid, L-serine, guanidine acetic acid, 3-hydroxyisovaleric acid, L-homoserine, L-cysteine, piperidine acid, hypotaurine and creatinine. The beverage is prepared from phenylacetic acid, erythritol, picolinic acid, taurine, pyroglutamic acid, lemonic acid, malic acid, tyramine, isonicotinic acid, o-phosphoethanolamine, L-glutamine, salicylic acid and D-glucose. The invention also provides a kit for detecting the plasma small molecule metabolism biomarker composition, the spectrum peak intensity of the obtained plasma small molecule metabolism biomarker is detected, the risk score of whether each subject is MetS or pre-MetS is calculated, and then whether the subject is MetS or pre-MetS is predicted. According to the invention, efficient and rapid diagnosis of the metabolic syndrome and the preclinical stage thereof is realized.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Salmonella typhimurium EN-VNP strain based on flagellin and LPS attenuation as well as preparation method and application of salmonella typhimurium EN-VNP strain

PendingCN120290433ABacteriaTransferasesEnzyme GenePhosphotransferase Gene
The invention discloses a salmonella typhimurium EN-VNP strain based on flagellin and LPS attenuation as well as a preparation method and application of the salmonella typhimurium EN-VNP strain, and particularly relates to the technical field of biology. The bacterial strain is formed by sequentially knocking out or silencing flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU on the basis of a salmonella VNP 20009 bacterial strain, and knocking in or overexpressing a phosphotransferase gene lpxE. The salmonella typhimurium EN-VNP strain disclosed by the invention has relatively high safety, the attenuated strain does not contain flagellin, and a lipid A molecule of LPS only retains one phosphate group, so that the safety of the strain is improved, and the strain is more suitable for serving as a vaccine and a drug delivery carrier.
Owner:JIANGSU TARGET BIOMEDICINE RES INST

A recombinant Escherichia coli capable of efficiently producing monophospholipid A vaccine adjuvant

The present invention discloses a recombinant Escherichia coli capable of efficiently producing monophospholipid A vaccine adjuvant, belonging to the fields of genetic engineering and synthetic biology. The present invention knocks out 132 genes related to membrane wall surface molecules, phospholipid and glucose transport, phosphoethanolamine modification and enoyl-ACP reductase in Escherichia coli MG1655, expresses lipid A modification genes FnlpxE, SepagP and SepagL, and constructs strain MW021 / pTEPL. The growth performance of MW021 / pTEPL is greatly improved and antibiotics and inducers are no longer required during the fermentation process; in a 2-L fermentation tank system, the highest OD of MW021 / pTEPL growth is 600 It can reach 38.54, and can produce 13.84g / L of dry cells and about 88.99mg / L of total lipid A; total lipid A contains only two structures, namely MPL and D-MPLA.
Owner:JIANGNAN UNIV

Ophthalmological composition containing at least one nicotinic acetylcholine receptor modulator for topical administration to the eye for preventing or treating inflammation of the eye

The present invention relates to an ophthalmological composition, comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, mecamylamine and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathways, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particular preference is given to choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (for example lecithin having a phosphatidylcholine content ≥ 80 wt.%, for example soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine.
Owner:URSAPHARM ARZNEIMITTEL

Flame-retardant skin-friendly polyurethane sponge with synergy of in-situ reaction and bio-enzyme catalysis

PendingCN121591997APolymer sciencePtru catalyst
The invention relates to a flame-retardant skin-friendly polyurethane sponge with in-situ reaction and bio-enzyme catalysis synergism. The water-based polyurethane foam is prepared from the following components: polyether polyol, diphenylmethane diisocyanate or toluene diisocynate, a chain extender, a high-efficiency foam stabilizer, a high-efficiency composite catalyst, water and ethanolamine phosphate, ethanolamine phosphate is added into water in advance, and then all the raw materials are mixed for polymerization foaming; after curing, spraying a spraying liquid consisting of phosphoethanolamine, regenerated protein and transglutaminase to generate a nano protein film, and synchronously performing vacuum suction to keep sponge pores unblocked. The preparation method has the advantages that a small amount of ethanolamine phosphate is added before polymerization foaming to serve as a phosphorus-nitrogen synergistic flame retardant and also serve as a catalytic cross-linking agent to participate in a reaction during polymerization, biological enzyme is added for catalysis after curing is finished, and the skin-friendly PU sponge with excellent flame retardance is prepared through in-situ polymerization reaction and biological enzyme enzymatic polymerization cooperation, and the sponge performance is not affected; the raw materials of the flame retardant come from biomass products and are environment-friendly and safe.
Owner:MLILY HOME TECHNOLOGY CO LTD

Preparation method and application of TEMP-coated Lip nano material

The invention provides a preparation method and application of a TEMP (Tetraethyl Methacrylate) Lip nano material, and the preparation materials of the TEMP Lip nano material comprise CH3CH2OH, CHCl3, THF (tetrahydrofuran), CH2Cl2, N (CH3) 3, NHS (N-Hydroxysuccinimide), 3-mercaptopropionic acid, 1, 3-dicyclohexylcarbodiimide, 4-amino-2, 2, 6, 6-tetramethylpiperidine, PBS (Phosphate Buffer Solution), alpha-GalCer, (2, 3-dioleoxy propyl) trimethyl ammonium chloride (DOTAP), 1, 2-dioleoyl-SN-glycerol-3-phosphorylethanolamine and dioleoyl phosphatidyl ethanolamine. The TEMP (at) Lip nano material is small in particle size and uniform in distribution, has negative potential, is good in corresponding biological solubility, is relatively stable in property after entering a living body, can safely transport an iNKT cell agonist, activates iNKT to improve the autoimmunity of the living body, and realizes the aim of treating tumors by using an autoimmune system.
Owner:河清(深圳)医学研究有限公司

Ophthalmic composition comprising at least one nicotinic acetylcholine receptor modulator for topical application to eye to prevent or treat inflammation of eye

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.
Owner:URSAPHARM ARZNEIMITTEL

Method for quantitative determination of phosphoethanolamine, oxidoreductase for quantitative determination, composition for quantitative determination, kit for quantitative determination, and sensor for quantitative determination

A novel quantitative method, an enzyme for quantitative determination, a quantitative kit, and a quantitative sensor for quantitative determination of the concentration of EAP, which is a biomarker of depression, are provided. A quantitative method for quantifying phosphoethanolamine is provided, wherein an oxidoreductase is added to a sample containing phosphoethanolamine. A mediator can be reduced by adding the oxidoreductase, and the reduced mediator can be reacted with a reagent to determine the concentration of the phosphoethanolamine. Alternatively, as the oxidoreductase, hydrogen peroxide generated by adding an oxidase can be reacted with a reagent to determine the concentration of the phosphoethanolamine.
Owner:KIKKOMAN CORP

Exosome with high permeability and application thereof

The invention relates to an exosome with high permeability and application of the exosome, and the surface of the exosome is connected with dioleoyl phosphatidylserine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine and hirudin. The exosome constructed by the invention can improve the permeability of the skin, can carry active components to directly reach the skin epidermis and corium layer, is accumulated on the epidermis and corium layer, continuously provides nutrition for the skin, and fully exerts the skin care and beautifying effects.
Owner:SHANGHAI KAIBAO ZHIYUAN BIOTECHNOLOGY CO LTD

Use of intracellular endogenous metabolites for the preparation of a medicament for the treatment and / or prevention of aging

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.
Owner:UNIV OF SCI & TECH OF CHINA

Chryseobacterium sp. Capable of degrading straw and inhibiting ralstonia solanacearum and application of Chryseobacterium sp.

The invention discloses a strain of Chryseobacterium wanjuense C14, and a preparation method of the Chryseobacterium wanjuense C14. The invention further discloses application of the bacillus subtilis in inhibition of ralstonia solanacearum and application of the bacillus subtilis in degradation of straw. The Chryseobacterium sp. C14 can obviously inhibit the growth of pathogenic bacteria of tomato bacterial wilt, especially under the assistance of tomato rhizosphere metabolites such as O-phosphoethanolamine, mangiferin and L-tryptophan, the antibacterial effect of the Chryseobacterium sp. C14 is further enhanced, and the Chryseobacterium sp. C14 has higher environmental adaptability and prevention and treatment potential. The Chryseobacterium sp. C14 can also degrade protein, cellulose and hemicellulose at the same time, and can significantly promote the degradation of rice straw and corn straw. The Chryseobacterium sp. C14 has the functions of straw degradation and tomato ralstonia solanacearum inhibition, integrates a soil-borne disease biological control function and efficient straw degradation, and provides a green and efficient microbial new strategy for solving the problems of difficult straw treatment and difficult tomato bacterial wilt control in agricultural production.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY

Sample pretreatment method for pyrite element analysis

The invention relates to a sample pretreatment method for pyrite elemental analysis. The method comprises the following steps: firstly, preparing a pretreatment agent: activating the surface of carboxymethyl chitosan by NHS / EDC, and then reacting with ethanolamine phosphate; secondly, a pyrite sample is taken and smashed into particles, the particles, NaOH, NaNO3 and a pretreatment agent are fully ground into powder, then the temperature is increased to 180-250 DEG C and then increased to 350-450 DEG C for heat preservation, sintered solids are transferred into a beaker, a hot nitric acid solution is added, the solids are dissolved through ultrasonic treatment, the solids are filtered into a volumetric flask after being cooled, and a to-be-tested sample is obtained after the volume is fixed through dilute nitric acid; according to the treatment method, use of a large amount of concentrated acid and perchloric acid is avoided, the reagent dosage is small, and environment friendliness is achieved; the recovery rate of 95% or above can be ensured when the treated sample is measured by instruments such as ICP-MS, the maximum RSD value does not exceed 5% compared with a standard value, and the accuracy is good.
Owner:COMPREHENSIVE TECH CENT FOR INSPECTION & QUARANTINE OF ZHANGJIAGANG ENTRY EXIT INSPECTION & QUARANTINE BUREAU

Molecular marker related to content of glyceryl phosphorylethanolamine in pig muscle and application of molecular marker

The invention discloses a molecular marker related to the content of glyceryl phosphorylethanolamine in pig muscle and application of the molecular marker. The invention provides an application of a substance for detecting the genotype of an SNP site in a pig genome in at least one of the following applications: A1) detecting or assisting in detecting the content state of glyceryl phosphorylethanolamine of a to-be-detected pig; a2) breeding pigs with high content of glyceryl phosphorylethanolamine; a3) pig breeding; and A4) preparing a product for detection or auxiliary detection of the content state of the glyceryl phosphorylethanolamine of the to-be-detected pig. According to the invention, by detecting the genotype of the pig to be detected at the SNP site, early selection of the content of glyceryl phosphoryl ethanolamine in pig muscle can be realized, the production cost can be saved, the genetic progress can be accelerated, and the SNP site has great economic application value and scientific research value.
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

An ophthalmic composition comprising at least one nicotinic acetylcholine receptor modulator for topical administration to the eye to prevent or treat ocular inflammation.

PendingJP2026529127AOphthalmologyPhosphorylcholine
The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.
Owner:URSAPHARM ARZNEIMITTEL

A sample pretreatment method for elemental analysis of pyrite

The application relates to a sample pretreatment method for pyrite element analysis. First, a pretreatment agent is prepared: carboxymethyl chitosan is activated on the surface through NHS / EDC, and then reacts with phosphoethanolamine to obtain the pretreatment agent; secondly, a pyrite sample is crushed into particles, and is fully ground into powder together with NaOH, NaNO3 and the pretreatment agent; then, the temperature is increased to 180-250 DEG C and then to 350-450 DEG C for heat preservation; the sintered solid is transferred into a beaker, hot nitric acid solution is added, ultrasonic is used to dissolve the solid, and after cooling, filtration is carried out into a volumetric flask, and dilute nitric acid is used for constant volume to obtain a sample to be tested. The treatment method avoids the use of a large amount of concentrated acid and perchloric acid, the reagent consumption is small, and the method is environment-friendly; the treated sample is determined by an ICP-MS instrument and the like, and the recovery rate can be ensured to be above 95%; compared with a standard value, the RSD value is not more than 5%, and the accuracy is good.
Owner:COMPREHENSIVE TECH CENT FOR INSPECTION & QUARANTINE OF ZHANGJIAGANG ENTRY EXIT INSPECTION & QUARANTINE BUREAU

Cationic immune liposome dry powder inhalant as well as preparation method and application thereof

The invention discloses a cationic immune liposome dry powder inhaler as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cationic immune liposome dry powder inhaler disclosed by the invention is prepared from siRNA (small interfering Ribonucleic Acid) used for KRAS mutation, (2, 3-dioleyloxypropyl)-trimethyl ammonium chloride, dipalmitic acid phosphatidylcholine, cholesterol, 1, 2-distearoyl-SN-glycerol-3-phosphorylethanolamine-N-maleimide-polyethylene glycol 2000, palbolizumab and a freeze-drying protective agent. The composition is prepared through a freeze-drying process. The preparation method of the dry powder inhaler comprises the following steps: preparing the cationic liposome carrying the siRNA, preparing the cationic immune liposome coupled with the antibody, and freeze-drying the dry powder inhaler. Compared with a traditional administration mode, the inhalant has the advantages of being simple in preparation process, good in drug stability, high in targeting performance, obvious in-vivo distribution advantage and the like, and a new strategy is provided for treatment of the non-small cell lung cancer.
Owner:YANTAI UNIV

Metabolic biomarker for diagnosing systemic lupus erythematosus and application thereof

The invention provides a metabolic biomarker for diagnosing systemic lupus erythematosus and application of the metabolic biomarker, and belongs to the technical field of biological medicines. The metabolic biomarker is at least one metabolite of sasol, ceramide phosphate and homoveratric acid. A reagent for detecting the expression quantity of the metabolic biomarker can be used for preparing a product for diagnosing systemic lupus erythematosus. The invention determines that the expression quantities of metabolites such as 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine, sasol, ceramide phosphate, homoveratric acid and the like in blood samples of an SLE patient and a healthy person have significant changes, so that the metabolite is put forward to be used as a biomarker for SLE disease diagnosis independently or in combination; the kit has the advantages of high accuracy, high sensitivity and high specificity, and provides a new target for diagnosis, intervention improvement and the like of SLE patients.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1

Metabolic marker combination for early diagnosis of kidney cancer and application thereof

The application provides a metabolic marker combination for early kidney cancer diagnosis and application thereof, and belongs to the technical field of in vitro diagnosis. The metabolic marker combination for early kidney cancer diagnosis comprises a first combination or a second combination. The first combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, methylphosphatidylcholine 33:2e and triglyceride 54:7. The second combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, L-threonyl-L-aspartic acid, iminodiacetic acid, triglyceride 56:8, O-phosphoethanolamine, methylphosphatidylcholine 33:2e and triglyceride 54:7. By detecting the metabolic marker combination in a blood sample, it can be determined whether a patient has early kidney cancer, has high sensitivity and specificity, can realize precise screening of early kidney cancer, and provides important help for prevention and reduction of the incidence of kidney cancer.
Owner:HARBIN METANOTITIA INC

Method for improving preparation efficiency of starch ester compound

The invention belongs to the technical field of food engineering, discloses a method for improving the preparation efficiency of a starch ester compound, and particularly relates to application of GSDL lipase OsGLIP11 in preparation of the starch ester compound. The invention discloses an amino acid sequence of OsGLIP11, which is shown in an ST.26 standard sequence nucleotide or amino acid sequence table. The starch is rice starch, and the lipid is 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine (DOPE) and 1, 2-distearoyl-sn-propyltriyl-3-phosphatidyl ethanolamine (DSPE), and the lipid is one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or more than one or By applying more active GDSL lipase OsGLIP11, the content of a starch ester compound formed by rice starch, DOPE and DSPE can be remarkably increased. According to the method disclosed by the invention, the GDSL lipase OsGLIP11 is added, so that the starch interacts with the exogenous lipid to generate the starch lipid compound more easily. The method can provide a theoretical reference for increasing the content of the resistant starch in the rice and further improving the digestion characteristic of the rice, and the high-resistant starch rice suitable for diabetics to eat is created.
Owner:CHINA NAT RICE RES INST

Combination immunization drug, temperature-sensitive gel composition, chemokine particle, and use thereof

The application discloses a combined immunization drug, a temperature-sensitive gel composition, a chemotactic factor particle and application thereof, and uses a mixed solution of an injectable temperature-sensitive polymer PLGA-PEG-PLGA, a chemotactic factor particle and an immune checkpoint inhibitor PD-1 monoclonal antibody to form a temperature-sensitive hydrogel beside a solid tumor at body temperature, and long-term controllable release of the chemotactic factor and aPD1, so as to enhance the targeting of adoptive T cells to the solid tumor and the resistance to immunosuppression in the tumor microenvironment. Through combination of the immunoregulatory temperature-sensitive gel and a tumor-penetrating peptide iRGD, the infiltration of the adoptive T cells to the solid tumor is enhanced, so that the solid tumor is efficiently treated. The chemotactic factor particle is constructed by using a distearoyl phosphoethanolamine-polyethylene glycol-N-hydroxysuccinimide modified chemotactic factor and an albumin carrier.
Owner:SUZHOU UNIV +1

Application of cell endogenous metabolite in preparation of medicine for treating and / or preventing senescence

ActiveCN119318660Areturn to normal growthImprove mitochondrial functionOrganic active ingredientsAntinoxious agentsEndogenous metabolismPremature aging
The invention discloses an application of a cell endogenous metabolite in preparation of a medicine for treating and / or preventing senescence. The cell endogenous metabolite is any one or a combination of more of phosphocreatine, hypotaurine and / or ethanolamine phosphate. The invention finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively recover cell growth, reduce SA-beta-Gal staining intensity of cells, improve mitochondrial functions of the cells, increase ATP yield, recover mitochondrial membrane potential of the cells and relieve damage and premature aging caused by oxidative stress of the cells under a specific concentration. The life of the nematodes can be prolonged; the exercise ability in the aging middle stage is recovered. Meanwhile, the three metabolites have a synergistic effect, and the same cell protection effect can be achieved by adjusting the proportioning concentration of the three metabolites and performing mixed administration. The endogenous metabolites have the characteristics of accuracy, high efficiency and safety at the same time, so that the three cell endogenous metabolites provided by the invention can be used for preparing anti-aging drugs.
Owner:UNIV OF SCI & TECH OF CHINA

Genetically engineered strains with reduced byproduct formation

ActiveUS20240409972A1BacteriaGenetically modified cellsGlucan biosynthesisPhosphorylethanolamine
The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.
Owner:DSM IP ASSETS BV

Use of gut microbiota or metabolite thereof, or antibody or derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer

PCT designated stageWO2026138837A1MetaboliteAntiendomysial antibodies
A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.
Owner:GUANGZHOU JUNCAI JIFANG BIOTECHNOLOGY CO LTD

Nucleic acid medicine for treating hepatocellular carcinoma as well as preparation method and application of nucleic acid medicine

The invention provides a nucleic acid medicinal preparation for treating hepatocellular carcinoma as well as a preparation method and application thereof, and belongs to the technical field of nucleic acid medicines. The invention provides a nucleic acid delivery carrier, which is prepared by compounding a neutral cytidine lipid material DNCA, a cystine skeleton cationic lipid material CLD and an auxiliary lipid material 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol DSPE-PEG according to a specific proportion. The invention also provides a nucleic acid medicine for treating hepatocellular carcinoma. The nucleic acid medicine comprises a nucleic acid delivery carrier, siRNA which is wrapped in the nucleic acid delivery carrier and is targeted to IGF1RmRNA, and a cell transfection solution. The nucleic acid medicine can efficiently target subcutaneous tumor parts of mouse hepatocytes, remarkably inhibits tumor growth and is free of liver and kidney toxicity. According to the technical scheme, a foundation is laid for wide clinical application of siRNA drugs for resisting hepatocellular carcinoma.
Owner:PEKING UNIV

Genetically engineered strains with reduced byproduct formation

ActiveUS12553071B2MicroorganismsGenetically modified cellsGlucan biosynthesisPhosphorylethanolamine
The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.
Owner:DSM IP ASSETS BV

Nano converter for inducing pyroptosis of cells as well as preparation method and application of nano converter

The invention discloses a nano converter for inducing pyroptosis of cells as well as a preparation method and application of the nano converter. The nano converter is prepared from the following raw materials: an energy donor, a photosensitizer, cholesterol oxidase and maleimide-1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-poly (ethylene glycol) (Mal-DSPE-PEG). In the nano converter, bisoxalate and chlorin e6 form a nano micelle with Mal-DSPE-PEG through hydrophilic and hydrophobic interaction, and cholesterol oxidase reacts with maleimide to be modified on the surface of the nano micelle. The nano converter can effectively convert cholesterol and hydrogen peroxide in tumor senescence cells into singlet oxygen to finally cause pyroptosis of the tumor senescence cells. The nano converter disclosed by the invention has the advantages of universality and high safety due to targeting of metabolic characteristics generally existing in tumor senescence cells. In addition, the nano converter utilizes chemical energy to drive photodynamic therapy, and possibly existing phototoxicity is reduced due to the fact that the nano converter does not depend on an external light source.
Owner:HUNAN UNIV